Andrew Spirito

Andrew Spirito is a turnaround expert in the Corporate Finance segment based in New York. Andrew has experience advising companies, lenders, creditors and equity sponsors across a diverse range of industries on both in- and out-of-court restructurings.

As an advisor, Andrew has assisted clients on a variety of matters spanning business strategy and planning, crisis management, cash and liquidity management and operational improvement. On behalf of clients, he has held a variety of interim roles within the finance, planning and transformation functions.

Andrew has experience in restructuring advisory and contingency planning, as well as the development and execution of cost reduction and liquidity improvement initiatives. He also has experience in budgeting, forecasting and cash management for healthy and distressed companies. Andrew has conducted operational and financial due diligence on behalf of lenders and managed pre-close diligence for financial sponsors. He also advises on and executes complex business carve-outs and merger integration efforts.

Relevant Experience:

• Served as head of operations finance for Invitae Corporation, conducting a strategic review of major products and assisting the organization with the development and execution of two business realignments; also supported the formal restructuring process and sale to Labcorp
• Served as head of financial planning and analysis (“FP&A”) for Zymergen, working with the management team to develop a business plan, capital allocation framework and liquidity forecast; also developed the projection model and supported the eventual sale process to Ginkgo Bioworks
• Advised Talis Biomedical on the evaluation of strategic alternatives and an orderly wind-down, including business planning, liquidity forecasting, cash preservation and asset sale support and the development of a distribution scheme to equity holders
• Developed the strategic long-range plan and detailed cost-takeout roadmap for Dendreon Corporation and supported the restructuring process as financial advisor, including contingency planning, negotiations with the noteholders and the M&A process culminating in the sale of the business to Valeant Pharmaceuticals
• Provided interim FP&A leadership and capital raise support for Diagnostic Testing Co, leading development of a detailed operating and commercial model with readout to the Board and management team
• Advised the Unsecured Creditors’ Committee of 23andMe through the Chapter 11 sale process, which culminated in a going-concern sale and a full recovery for his clients